Thomas Holm Pedersen, NMD Pharma CEO (file photo)
Roche-backed biotech refuels with $40M to steer neuromuscular candidate toward late-stage trials
Four years after receiving backing from Roche to see if it can carve out a unique path in rare neuromuscular disorders, Aarhus, Denmark-based NMD Pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.